Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | KDM1A | O60341 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16822146 | 1.00 | KMT2A (0.32) | KMT2AL3MBTL1CYP3A4KDM1AMAOB | |
| SCHEMBL16822138 | 1.00 | KMT2A (0.32) | KMT2AL3MBTL1CYP3A4KDM1AMAOB | |
| SCHEMBL14616110 | 0.74 | — | — | |
| SCHEMBL601185 | 0.74 | — | — | |
| SCHEMBL27488909 | 0.74 | — | — | |
| SCHEMBL29043547 | 0.74 | CYP3A4 (0.32) | L3MBTL1CYP3A4GAA | |
| SCHEMBL3790014 | 0.72 | — | — | |
| SCHEMBL12166731 | 0.72 | CYP3A4 (0.31) | L3MBTL1CYP3A4GAA | |
| SCHEMBL11949633 | 0.70 | — | — | |
| Hydrochloric Acid SCHEMBL3780696 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110582485-B | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| EP-3589618-B1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2022-12-28 | — | — | EP | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-04-06 | — | — | US | disclosed |
| EP-3736268-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS | Signal Pharmaceuticals, LLC (US) | 2020-11-11 | — | — | EP | disclosed |
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| EP-3082819-B1 | SUBSTITUTED DIAMINOPYRIMIDYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARM LLC (US) | 2020-06-17 | — | — | EP | disclosed |
| CN-110582485-A | Pyrazole derivatives as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2019-12-17 | — | — | CN | disclosed |
| WO-2018158212-A1 | PYRAZOLE DERIVATIVES AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-07 | — | — | WO | disclosed |
| US-8389536-B2 | Positive allosteric modulators (PAM) | HOFFMANN-LA ROCHE INC. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2493856-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. Hoffmann-La Roche AG (CH) | 2012-09-05 | — | — | EP | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| WO-2011051201-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | F. HOFFMANN-LA ROCHE AG (CH) | 2011-05-05 | — | — | WO | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | HOFFMANN-LA ROCHE, INC. | 2011-04-28 | — | — | US | disclosed |
| EP-0225535-B1 | CROSS-LINKED COPOLYMERS IN PEARL FORM CONTAINING EPOXY AND BASIC AMINO GROUPS, PROCESS FOR THEIR PREPARATION AND THEIR USE | BAYER AG (DE) | 1991-05-15 | — | — | EP | disclosed |
| US-4772635-A | Bead-shaped crosslinked copolymers containing epoxide groups and basic amino groups, a process for their preparation and their use | BAYER AKTIENGESELLSCHAFT (DE) | 1988-09-20 | — | — | US | disclosed |
| EP-0225535-A2 | Cross-linked copolymers in pearl form containing epoxy and basic amino groups, process for their preparation and their use | BAYER AG (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10966961-B2 | Pyrazole derivatives as bromodomain inhibitors | BRD3, BRD4, BRPF3 | KMT2A 1291/4885L3MBTL1 4020/4885CYP3A4 860/4885 |
| US-20110098313-A1 | POSITIVE ALLOSTERIC MODULATORS (PAM) | GRM5, GRM1, GRM2 | KMT2A 2147/4885L3MBTL1 2928/4885CYP3A4 3596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.